◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Dr. Reddy’s Laboratories Ltd ADR (RDY)

Name: Dr. Reddy’s Laboratories Ltd ADR（RDY）— 財務諸表の推移
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

HEALTHCARE · ウォール街（米国） · 最終更新: 2026-07-29

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

主要指標

時価総額: INR 10 billion
売上高（2026-03-31 期末の会計年度）: INR 353.5B
当期純利益: INR 45.1B
売上総利益率: 52.8%
純利益率: 12.8%

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→

年次損益計算書

損益計算書	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31	2009-03-31	2008-03-31	2007-03-31
売上高合計	INR 332.8B	INR 353.5B	INR 325.5B	INR 279.2B	INR 245.9B	INR 214.4B	INR 2.6B	INR 174.6B	INR 153.9B	INR 142.0B	INR 140.8B	INR 154.7B	INR 148.2B	INR 132.2B	INR 116.3B	INR 96.7B	INR 74.7B	INR 70.3B	INR 69.4B	INR 50.0B	INR 65.2B
売上総利益	INR 166.9B	INR 186.5B	INR 190.4B	INR 163.6B	INR 139.3B	INR 113.8B	INR 1.3B	INR 94.0B	INR 83.4B	INR 76.3B	INR 78.4B	INR 92.3B	INR 85.4B	INR 75.8B	INR 60.6B	INR 53.3B	INR 40.3B	INR 36.3B	INR 36.5B	INR 25.4B	INR 30.9B
売上総利益率 %	50.1%	52.8%	58.5%	58.6%	56.7%	53.1%	50.8%	53.8%	54.2%	53.7%	55.6%	59.7%	57.6%	57.4%	52.1%	55.1%	53.9%	51.7%	52.6%	50.8%	47.4%
営業利益（EBIT）	INR 35.2B	INR 48.9B	INR 71.8B	INR 67.7B	INR 57.1B	INR 29.5B	INR 431M	INR 16.0B	INR 20.9B	INR 11.9B	INR 13.5B	INR 29.6B	INR 26.3B	INR 26.0B	INR 21.1B	INR 18.3B	INR 12.6B	INR 2.0B	(INR 2.8B)	INR 3.4B	INR 11.3B
営業利益率 %	10.6%	13.8%	22.1%	24.3%	23.2%	13.8%	16.9%	9.2%	13.6%	8.4%	9.6%	19.1%	17.7%	19.7%	18.2%	18.9%	16.9%	2.9%	-4.1%	6.7%	17.2%
当期純利益	INR 33.2B	INR 45.1B	INR 56.5B	INR 55.7B	INR 45.1B	INR 23.6B	INR 232M	INR 19.5B	INR 18.8B	INR 9.8B	INR 12.0B	INR 20.0B	INR 22.2B	INR 21.5B	INR 16.8B	INR 14.3B	INR 11.0B	INR 1.1B	(INR 5.2B)	INR 4.7B	INR 9.3B
純利益率 %	10.0%	12.8%	17.4%	20.0%	18.3%	11.0%	9.1%	11.2%	12.2%	6.9%	8.6%	12.9%	15.0%	16.3%	14.4%	14.7%	14.8%	1.5%	-7.4%	9.4%	14.3%
EBITDA	INR 55.6B	INR 83.3B	INR 96.7B	INR 88.4B	INR 74.4B	INR 45.1B	INR 535M	INR 41.8B	INR 35.5B	INR 23.6B	INR 24.8B	INR 39.9B	INR 34.4B	INR 33.1B	INR 22.5B	INR 20.3B	INR 16.8B	INR 6.6B	INR 1.5B	INR 7.3B	INR 14.3B
1株当たり利益（EPS）	INR 39.81	INR 54.11	INR 67.77	INR 66.80	INR 54.17	INR 28.34	INR 0.28	INR 23.48	INR 22.62	INR 11.80	INR 14.42	INR 23.40	INR 25.95	INR 25.21	INR 19.69	INR 16.76	INR 12.99	INR 1.26	INR -6.14	INR 5.55	INR 11.74
発行済株式数（百万株）	833M	833M	834M	834M	832M	832M	832M	830M	831M	831M	835M	855M	855M	853M	852M	851M	850M	848M	842M	843M	796M

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は RDY のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/RDY

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.